肿瘤药学Issue(5)：357-361,5.DOI:10.3969/j.issn.2095-1264.2015.05.08
两种联合化疗方案治疗晚期膀胱癌的临床评价及药物经济学分析
Clinical Efficacy and Pharmacoeconomics Analysis on Two Kinds of Combination Chemotherapy Regimen for Advanced of Bladder Cancer
林劲冠 1崔自重 1何喆 1张红艳1
作者信息
- 1. 中南大学湘雅医学院附属肿瘤医院，湖南 长沙，410013
- 折叠
摘要
Abstract
Objective:Objective To compare the curative effects and economy of two therapy regimens for advanced bladder cancer, which were cisplatin plus methotrexate, VLB and adriamycin (MVAC) regimen and cisplatin plus gemcitabine (GC) regimen. Methods The data were retrospectively analyzed of 172 patients with bladder cancer chemotherapy. The patients were randomly divided into MVAC group (n=86) and GC group (n=86). After treatment, the clinical curative effects were analyzed, and their pharmacoeconomics was evaluated with the cost-effectiveness analysis method. Results The ratios of clinical curative efficacy of the MVAC and GC groups were 52.3%and 59.3%respectively, having no significant differ-ences between the two groups (P>0.05). The cost-efficient ratios of MVAC group and GC group were 348.64 and 247.17 respectively, and the differences were statistically significant between the two groups (P<0.05) in this respect. The adverse reactions mainly were hematological toxicity and digestive tract reaction in both groups, and there was no statistically sig-nificant difference between them. Conclusion As for the treatment of disease, the therapeutic schedule of GC has more cost effectiveness, but the therapeutic schedule of MVAC is better in disease control.关键词
晚期膀胱癌/顺铂/联合化疗/吉西他滨/药物经济学Key words
Advancedbladdercancer/Cisplatin/Combinationchemotherapy/Gemcitabine/Pharmacoeconomics分类
医药卫生引用本文复制引用
林劲冠,崔自重,何喆,张红艳..两种联合化疗方案治疗晚期膀胱癌的临床评价及药物经济学分析[J].肿瘤药学,2015,(5):357-361,5.
